This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

Continuing Education Instructions and Disclosure Information:

Contact hours available until 5/10/2025.

Requirements for Successful Completion:

Complete the learning activity in its entirety and complete the online nursing continuing professional development (NCPD) evaluation. You will be able to print your NCPD certificate at any time after you complete the evaluation.

Disclosure of relevant financial relationships with ineligible companies (planners, faculty/speakers, reviewers):

Planning Committee Disclosures:
Christine Corbett, DNP, FNP-BC, CNN-NP, FNKF – Consultant/Speakers Bureau for GSK Anemia.
Leah Foster Smith, MSN, APRN, FNP-BC, CNN-NP, FNKF – Owner and Chief Education Officer for Interactive Nephrology

There are no other Planning Committee disclosures to declare.

Speaker Disclosures:

Debra Castner - Speakers Bureau, AstraZeneca

David Cherney - Consultant and Speaker, Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, Abbvie, Janssen, Bayer, Prometic, BMS, Maze, Gilead, CSL-Behring, Otsuka, Novartis, Youngene, Lexicon, Inversago, Novo-Nordisk

Csaba Kovesdy – Consultant, Abbott, Akebia, CSL Behring, CSL Vifor, Rockwell, AstraZeneca, Bayer, Boehringer Ingelheim, Cara Therapeutics, GSK

There are no other speaker disclosures to declare.

Commercial Support:
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

Accreditation Statement:
The American Nephrology Nurses Association (ANNA) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

ANNA is an approved provider of continuing nursing education by the California Board of Registered Nursing, Provider Number CEP 17499.

ANNA urges participants to be aware of the CE requirements for re-licensure in the states in which they hold a license.

Learning Outcome:
After completion of this learning activity, participants will be able to discuss optimizing outcomes in CKD patients related to new evidence concerning the use of new therapies for hyperkalemia management and SGLT2 inhibitors.

Credits Available